Successful use of BRAF/MEK inhibitors as a neoadjuvant approach in the definitive treatment of papillary craniopharyngioma

Keyphrases

• Definitive Treatment 100%
• Neoadjuvant 100%
• BRAF Inhibitor (BRAFi) 100%
• Papillary Craniopharyngioma 100%
• Targeted Therapy 66%
• Neuroanatomy 66%
• Craniopharyngioma 66%
• Suprasellar Region 66%
• Tumor 33%
• Somatic mutation 33%
• High Morbidity 33%
• Medical Therapy 33%
• Optic Nerve 33%
• Radiation Therapy 33%
• Neuroanatomical 33%
• BRAF V600E 33%
• Stereotactic Radiosurgery 33%
• Multidisciplinary Approach 33%
• Surgical Therapy 33%
• Rare Tumors 33%
• Trametinib 33%
• Neoadjuvant Setting 33%
• Pathway Inhibitors 33%
• WHO Grade I 33%
• Dabrafenib 33%
• Dual Targeted Therapy 33%
• Sellar-suprasellar 33%
• Mitogen-activated Protein Kinase Inhibitor 33%

Medicine and Dentistry

• MEK Inhibitor 100%
• Craniopharyngioma 100%
• Targeted Therapy 60%
• Neuroanatomy 40%
• Neoplasm 20%
• Somatic Mutation 20%
• Combination Therapy 20%
• Optic Nerve 20%
• Stereotactic Radiosurgery 20%
• Rare Tumor 20%
• Trametinib 20%
• Dabrafenib 20%
• Surgery 20%
• Radiation Therapy 20%

Neuroscience

• MEK Inhibitor 100%
• Craniopharyngioma 100%
• Neuroanatomy 40%
• Optic Nerve 20%
• Somatics 20%
• Trametinib 20%
• Dabrafenib 20%